HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gastroenterology
Phase II
Tislelizumab plus chemotherapy and radiotherapy yields 89.1% 3-year disease-free survival in pMMR/MSS locally advanced rectal cancer
Early trial shows high survival rates for rectal cancer patients treated with tislelizumab
This Phase 2 clinical trial evaluated neoadjuvant tislelizumab, chemotherapy, and long-course radiotherapy in 50 patients with pMMR/MSS loca…
A Phase 2 trial found that adding tislelizumab to standard care helped 89% of patients stay free of cancer for three years. This approach wo…
May 1, 2026
Oncology
Cohort
MRI-derived nomogram improves high-risk LARC stratification over single-feature models in a multicenter retrospective cohort.
New MRI Tool Pinpoints Which Rectal Cancer Patients Need Intensive Treatment
This multicenter retrospective cohort study evaluated a nomogram integrating habitat heterogeneity, peritumoral (3 mm) radiomic features, an…
This new approach could spare some patients from harsh treatments while ensuring others get the aggressive care they need.
Frontiers
Apr 21, 2026
Oncology
RCT
Neoadjuvant CAPOX chemotherapy alone showed comparable survival to chemoradiotherapy in locally advanced rectal cancer with uninvolved mesorectal fascia.
Some Rectal Cancer Patients May Skip Radiation Without Losing Ground
This Phase III RCT compared 4 cycles of CAPOX chemotherapy alone versus chemoradiotherapy in patients with locally advanced rectal cancer an…
Some rectal cancer patients can skip pre-surgery radiation and still achieve similar cure rates while avoiding long-term side effects like b…
Apr 13, 2026
Gastroenterology
RCT
Dynamic ctDNA monitoring during neoadjuvant chemotherapy identifies high-risk rectal cancer patients
Blood test during chemo may help predict rectal cancer treatment response
A biomarker substudy of a multicenter RCT in 153 patients with low-/intermediate-risk locally advanced rectal cancer found that dynamic ctDN…
A blood test tracking tumor DNA during chemo can predict which rectal cancer patients won't respond well to treatment before surgery.
Apr 8, 2026
Gastroenterology
Phase II
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
CT.gov
Mar 30, 2026